Literature DB >> 23635797

Understanding the growth hormone therapy adherence paradigm: a systematic review.

Benjamin G Fisher1, Carlo L Acerini.   

Abstract

INTRODUCTION: Growth hormone (GH) therapy is used to treat a variety of growth disorders in childhood/adolescence. Its efficacy is thought to be dependent on patients' adherence to their treatment regimen.
METHODS: PubMed was searched using the keywords 'growth hormone', 'child'[Mesh], 'adolescent'[Mesh], and 'patient compliance'[Mesh].
RESULTS: Most studies of adherence to paediatric GH therapy have used either issued/encashed GH prescriptions or questionnaires. Estimates of prevalence of non-adherence vary from 5-82%, depending on the methods and definitions used. Different studies have variously demonstrated an association (or lack thereof) between adherence and age, socioeconomic status, treatment duration, injection device used and injection-giver. A number of interventions have been proposed to improve adherence, including offering a choice of injection device, but none are supported by trials. Poor adherence is associated with reduced height velocity and likely increased economic costs; evidence for other effects is circumstantial.
CONCLUSION: Adherence to paediatric GH therapy is suboptimal, which may partially explain why the mean final height attained is below that of the general population. Analysis of the causes of non-adherence is complicated by conflicting evidence from different studies. Multifactorial interventions are most likely to be successful in improving adherence. We make recommendations for further research.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23635797     DOI: 10.1159/000350251

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  49 in total

Review 1.  Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding.

Authors:  Julia G Halas; Adda Grimberg
Journal:  Minerva Pediatr       Date:  2020-04-09       Impact factor: 1.312

2.  Use of machine learning to identify patients at risk of sub-optimal adherence: study based on real-world data from 10,929 children using a connected auto-injector device.

Authors:  Amalia Spataru; Paula van Dommelen; Lilian Arnaud; Quentin Le Masne; Silvia Quarteroni; Ekaterina Koledova
Journal:  BMC Med Inform Decis Mak       Date:  2022-07-06       Impact factor: 3.298

3.  Investigating the Impact of the TUITEK® Patient Support Programme, Designed to Support Caregivers of Children Prescribed Recombinant Human Growth Hormone Treatment in Taiwan.

Authors:  Pen-Hua Su; Sumaira Malik; Amrit Jheeta; Yen-Fan Lin; Su-Huei Su; Ekaterina Koledova; Selina Graham
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-06       Impact factor: 6.055

Review 4.  Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care.

Authors:  Martin O Savage; Luis Fernandez-Luque; Selina Graham; Paula van Dommelen; Matheus Araujo; Antonio de Arriba; Ekaterina Koledova
Journal:  Patient Prefer Adherence       Date:  2022-07-11       Impact factor: 2.314

5.  Integrated Digital Health Solutions in the Management of Growth Disorders in Pediatric Patients Receiving Growth Hormone Therapy: A Retrospective Analysis.

Authors:  Vincenzo Tornincasa; David Dixon; Quentin Le Masne; Blaine Martin; Lilian Arnaud; Paula van Dommelen; Ekaterina Koledova
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

6.  Psychometric Validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB).

Authors:  Meryl Brod; Michael Højby Rasmussen; Suzanne Alolga; Jane F Beck; Donald M Bushnell; Kai Wai Lee; Aristides Maniatis
Journal:  Pharmacoecon Open       Date:  2022-10-18

Review 7.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

8.  Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope®: a questionnaire-based observational study conducted in paediatric patients in France.

Authors:  Régis Coutant; Clémentine Dupuis; Patricia Pigeon; Phillipe Rebaud
Journal:  Ther Adv Endocrinol Metab       Date:  2017-10-02       Impact factor: 3.565

9.  Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency.

Authors:  George M Bright; Minh-Ha T Do; John C McKew; Werner F Blum; Michael O Thorner
Journal:  J Endocr Soc       Date:  2021-02-25

10.  Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study.

Authors:  Carl-Joachim Partsch; Dirk Schnabel; Sarah Ehtisham; Helen C Johnstone; Markus Zabransky; Wieland Kiess
Journal:  Med Devices (Auckl)       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.